Volume 72, Issue 3, Pages (August 2007)

Slides:



Advertisements
Similar presentations
Volume 66, Issue 1, Pages (July 2004)
Advertisements

Inflammatory cytokines in acute renal failure
Volume 74, Issue 3, Pages (August 2008)
Volume 60, Issue 3, Pages (September 2001)
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells  B. Zhang, G. Ramesh, C.C. Norbury, W.B. Reeves 
Metabolomic study of cisplatin-induced nephrotoxicity
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
Fibrate prevents cisplatin-induced proximal tubule cell death
Volume 78, Issue 11, Pages (December 2010)
Volume 85, Issue 3, Pages (March 2014)
Volume 68, Issue 2, Pages (August 2005)
Volume 68, Issue 6, Pages (December 2005)
Li-Wen Lai, Kim-Chong Yong, Yeong-Hau H. Lien  Kidney International 
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Volume 86, Issue 1, Pages (July 2014)
Volume 71, Issue 3, Pages (February 2007)
Volume 72, Issue 4, Pages (August 2007)
Volume 82, Issue 8, Pages (October 2012)
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Volume 84, Issue 2, Pages (August 2013)
Volume 62, Issue 4, Pages (October 2002)
Volume 63, Issue 1, Pages (January 2003)
Volume 74, Issue 3, Pages (August 2008)
Volume 75, Issue 2, Pages (January 2009)
Genistein protects the kidney from cisplatin-induced injury
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis  Hua Liu, Radhakrishna Baliga  Kidney International 
Volume 73, Issue 5, Pages (March 2008)
Vitamin E attenuates crystal formation in rat kidneys: Roles of renal tubular cell death and crystallization inhibitors  H.-S. Huang, J. Chen, C.-F. Chen,
Volume 73, Issue 4, Pages (February 2008)
Volume 82, Issue 9, Pages (November 2012)
Volume 73, Issue 4, Pages (February 2008)
Volume 63, Issue 2, Pages (February 2003)
Autophagy in proximal tubules protects against acute kidney injury
Volume 69, Issue 12, Pages (June 2006)
Decreased renal ischemia–reperfusion injury by IL-16 inactivation
Volume 79, Issue 1, Pages (January 2011)
Role of meprin A in renal tubular epithelial cell injury
Volume 60, Issue 3, Pages (September 2001)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Volume 79, Issue 9, Pages (May 2011)
Volume 89, Issue 2, Pages (February 2016)
Volume 76, Issue 10, Pages (November 2009)
Gene transfer of truncated IκBα prevents tubulointerstitial injury
Volume 66, Issue 6, Pages (December 2004)
Renoprotective role of the vitamin D receptor in diabetic nephropathy
Kenji Kasuno, Hajime Nakamura, Takahiko Ono, Eri Muso, Junji Yodoi 
Volume 73, Issue 5, Pages (March 2008)
Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin- induced acute kidney injury  K. Negishi, E. Noiri, R. Maeda, D.
Volume 56, Issue 4, Pages (October 1999)
Volume 73, Issue 11, Pages (June 2008)
Wei-Zhong Ying, Pei-Xuan Wang, Paul W. Sanders  Kidney International 
Volume 66, Issue 5, Pages (November 2004)
Volume 60, Issue 6, Pages (December 2001)
Volume 71, Issue 7, Pages (April 2007)
Volume 66, Issue 1, Pages (July 2004)
The pathological role of Bax in cisplatin nephrotoxicity
Volume 58, Issue 2, Pages (August 2000)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Hideyuki Murakami, Katsutoshi Yayama, Lee Chao, Julie Chao 
M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang 
Volume 74, Issue 8, Pages (October 2008)
LncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy  Juan Wang, Jian Pang, Huiling Li, Jie Long, Fang Fang, Junxiang Chen,
MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis  Sang-Kyung Jo, Won Yong Cho, Su Ah Sung, Hyoung.
Volume 67, Issue 4, Pages (April 2005)
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Volume 69, Issue 3, Pages (February 2006)
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure  D.W. Johnson, B. Pat, D.A. Vesey, Z.
IL-1β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells  D. Solà-Villà, M. Camacho, R. Solà,
Volume 78, Issue 3, Pages (August 2010)
The GCN2 eIF2α Kinase Regulates Fatty-Acid Homeostasis in the Liver during Deprivation of an Essential Amino Acid  Feifan Guo, Douglas R. Cavener  Cell.
Presentation transcript:

Volume 72, Issue 3, Pages 348-358 (August 2007) A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure  K. Negishi, E. Noiri, T. Sugaya, S. Li, J. Megyesi, K. Nagothu, D. Portilla  Kidney International  Volume 72, Issue 3, Pages 348-358 (August 2007) DOI: 10.1038/sj.ki.5002304 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Effect of fibrate WY-14643 (WY) on renal function in mice after single dose of CP. Mice were fed with either a regular diet or a diet containing 0.1% WY for 7 days before CP administration, as described in Materials and Methods. BUN and creatinine levels were measured at days 1, 2, and 3 after saline (control)-, CP-, or CP+WY-treated mice. Bars correspond to mean±s.e. of at least six independent experiments under each condition. Changes in (a) BUN and (b) creatinine levels, respectively, after saline or CP administration in PPARα wild-type mice. *P<0.005 when animals were compared with control by unpaired Student's t-test. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 2 Effect of fibrate and cisplatin on PMP70 expression in kidney tissue. (a) Time course of the effect of CP on PMP70 protein expression in kidney tissue. Mice were administered saline (control) or CP (20 mg/kg body weight) by a single intraperitoneal injection. Western blot analysis of kidney tissue homogenates at days 1, 2, and 3 after CP injection using a PMP70 antibody as described in Materials and Methods. Bars correspond to mean±s.e. of at least three independent experiments under each condition. (b) Effect of fibrate (WY) and CP on PMP70 protein expression. Mouse kidney tissue homogenates were prepared from animals subjected to four experimental conditions, and Western blots were performed as described in Materials and Methods. PMP-70 protein levels were normalized using β-actin as internal control. Bars correspond to mean±s.e. of at least three independent experiments under each condition. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 3 Effect of fibrate (WY) and CP on catalase protein expression. Mouse kidney tissue homogenates were prepared from animals subjected to four experimental conditions, and Western blots were performed as described in Materials and Methods. Catalase protein levels were normalized using β-actin as internal control. Bars correspond to mean±s.e. of at least three independent experiments under each condition. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 4 Effect of fibrate (WY) and CP on peroxisomal distribution. (a) Mouse kidney sections from animals subjected to four experimental conditions (a) control, (b) fibrate (WY), (c) CP, and (d) WY+CP were stained with PMP70 antibody as described in Materials and Methods. (e) Quantitative analysis of pixel densities of the peroxisomal population present in the four experimental conditions was performed as described in the Materials and Methods section. Bars correspond to mean±s.e. of at least four independent experiments under each condition. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 5 Effect of CP and fibrate on mL-FABP mRNA levels in SV-129 wild-type mice. Mice that received either a normal diet or a diet containing fibrate (WY) for 7 days were injected with saline (control) or CP and then killed at the indicated times. Levels of mL-FABP mRNA was measured by real-time reverse transcriptase-polymerase chain reaction as described in Materials and Methods. Figure shows relative mL-FABP gene expression in saline (control), CP-, CP+fibrate-, and fibrate-treated mice normalized by 28S rRNA expression. Values are mean±s.e. mRNA levels. Data were obtained from at least three independent experiments. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 6 Effect of CP and Wy on L-FABP protein levels in SV-129 wild-type (+/+) and PPARα null (-/-) mice. (a) Effect f of CP and WY on L-FABP protein levels in SV-129 wild-type (+/+) mice. The immunoblot analysis of mouse kidney tissue homogenates from four different experimental conditions was performed as described in Materials and Methods. β-Actin antibody was used as an internal control for normalizing the L-FABP protein levels. Bars correspond to mean±s.e. of at least three independent experiments under each condition. *P<0.005 when animals were compared with control by unpaired Student's t-test. (b) Effect f of CP and fibrate on L-FABP protein levels in sv-129 PPARα knock out (-/-) mice. The immunoblot analysis of mouse kidney tissue homogenates from four different experimental conditions was performed as described in Materials and Methods. Kidney homogenate from wild-type mice treated with fibrate (WY) was run as positive control for L-FABP protein. β-Actin antibody was used as an internal control for normalizing the L-FABP protein levels. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 7 Immunolocalization of mL-FABP. Representative picture of kidney sections from (a) control-, (b) fibrate (WY)-, (c) CP-, and (d) WY+CP-treated mice stained with anti-mL-FABP antibody. Positive immunostaining was apparent only in fibrate and fibrate+CP-treated mice predominantly in proximal tubules (PT) of the outer cortex (arrows). Original magnification × 122. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 8 Effect of Bz on renal function in h-L-FABP transgenic mice after single dose of CP. Mice were fed with either a regular diet or a diet containing 0.1% Bz for 7 days before CP administration, as described in Materials and Methods. BUN and creatinine levels were measured at days 1, 2, and 3 after saline control (NS)-, CP (CP)-, CP+Bz (CP+BZ)-, or saline+Bz (BZ+NS)-treated mice. Bars correspond to means±s.e. of at least 10 independent experiments under each condition. (a) Changes in BUN and (b) creatinine levels, respectively, after saline or CP administration in PPARα wild-type mice. *P<0.05 when CP+Bz group was compared with CP alone group by unpaired Student's t-test. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 9 Effect of BZ on urinary h-L-FABP levels after single dose of CP. Urinary h-L-FABPlevels were measured at days 1, 2, and 3 after saline control (NS)-, CP (CP)-, CP+BZ (CP+BZ)-, or saline+Bz (BZ)-treated mice by enzyme-linked immunosorbent assay as described in Materials and Methods. * Represents P<0.05 when urinary h-L-FABP levels were compared at day 3 and day 2 after CP administration. ** Represents P<0.05 when urinary h-L-FABP levels were compared at day 2 versus day 1 and day 0, and # represents P<0.05 when urinary h-L-FABP levels were compared among all the four groups. Bars correspond to mean±s.e. of at least seven independent experiments under each condition. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 10 Immunolocalization of h-L-FABP in h-L-FABP transgenic mice. (a) There was no positive immunoreactivity for h-L-FABP in kidneys from control C57Bl wild-type non-transgenic mice. (b) Untreated h-L-FABP transgenic animals showed strong positive staining in the cytoplasm of early (S1 and S2) segments of proximal tubules (PT). (c) CP administration caused a positive nuclear staining for h-L-FABP in the epithelium of Bowman capsule and early (S1 and S2) segments of proximal tubules (PT) (arrows). (d) The Bz+CP-treated mice showed strong cytoplasmic staining in proximal tubules (PT) of the deep cortex (S3 segment) (arrows). Glomeruli (G) and distal nephron segment were mainly negative. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 11 Effect of Bz on kidney morphology in h-L-FABP transgenic mice after single dose of CP. Kidney morphology of h-L-FABP transgenic mice after 72 h of (a and c) CP exposure and after treatment with (b and d) Bz+CP. Severe tubular necrosis was seen in the proximal tubules (S1 and S2) of the outer cortex of (a) CP-treated mice (*). Bz significantly ameliorated necrosis of proximal tubules (PT) caused by (b) CP injection. Proximal tubules of the deep cortex (S3 segment) (PT) showed PAS-positive droplet accumulation in their cytoplasm in (c) CP-treated mice (arrows), which was ameliorated by (d) Bz pretreatment (arrows). (e) Quantitative evaluation of morphologic kidney damage of h-L-FABP transgenic mice after CP and Bz+CP. Values are expressed as relative severity on a scale from 0 to 4 and represent mean±s.e. of kidney sections from at least eight mice for each experimental condition. Morphology was scored according to proximal tubule necrosis (Necrosis), brush border loss (BB Loss), cast formation within tubules (Casts), tubule dilation (Dilatation), and tubular degeneration (Degen). Statistically significant differences (P<0.05) are indicated. Kidney International 2007 72, 348-358DOI: (10.1038/sj.ki.5002304) Copyright © 2007 International Society of Nephrology Terms and Conditions